貝達藥業(300558.SZ)獲EYP-1901在中國獨家開發和商業化權利
格隆匯5月5日丨貝達藥業(300558.SZ)公佈,2022年5月4日,公司與EyePoint Pharmaceuticals, Inc.(簡稱“EyePoint”)簽署《擴大許可協議》,就EYP-1901在中國(包括香港、澳門和台灣)區域的開發和商業化進行獨家合作。
同時,公司控股子公司Equinox與EyePoint修訂了《獨佔許可協議》,獨家授權EyePoint在中國(包括香港、澳門和台灣)區域外開發伏羅尼布用於所有局部給藥的眼科適應症,包括糖尿病黃斑水腫(DME)。
據悉,EyePoint是一家專業的製藥公司,致力於開發和商業化針對眼部疾病的創新治療方案,以幫助改善嚴重眼部疾病患者的生活,其股票於美國NASDAQ證券交易所上市交易。
該公司目前有DEXYCU®、YUTIQ®兩款商業化產品,其中DEXYCU®是治療術後炎症的眼內產品,YUTIQ®是對影響眼球后段的慢性非感染性葡萄膜炎進行為期三年治療的產品。
貝達藥業表示,該次擴大許可協議的簽訂進一步深化了公司和EyePoint之間的合作,可以發揮公司在新藥開發及商業化方面的能力和優勢,加快EYP-1901的臨牀開發,儘早為嚴重眼科疾病患者提供一種新的局部注射治療方案響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.